To confirm this finding, we repeated the IRE + anti-PD1 treatment in additional 7 KRAS*-bearing mice: 3 of these 7 mice (43%) reached the 60-day study endpoint with no palpable tumor (Supplementary Figure 1). The gene discussed is KRAS; the disease is neoplasm.